GENFIT (NASDAQ:GNFT) Coverage Initiated by Analysts at HC Wainwright

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Research analysts at HC Wainwright began coverage on shares of GENFIT (NASDAQ:GNFT - Get Free Report) in a report released on Tuesday, MarketBeat.com reports. The brokerage set a "buy" rating and a $9.00 price target on the stock. HC Wainwright's price objective indicates a potential upside of 108.53% from the company's current price. HC Wainwright also issued estimates for GENFIT's FY2025 earnings at $0.01 EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.24) EPS, FY2028 earnings at ($0.90) EPS and FY2029 earnings at ($0.64) EPS.

GENFIT Stock Up 4.8%

GNFT stock traded up $0.1960 during trading on Tuesday, hitting $4.3160. 1,582 shares of the stock traded hands, compared to its average volume of 3,812. GENFIT has a one year low of $2.55 and a one year high of $6.42. The company has a 50 day simple moving average of $3.90 and a 200 day simple moving average of $3.85. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 0.08.

Institutional Investors Weigh In On GENFIT

A hedge fund recently bought a new stake in GENFIT stock. OLD Mission Capital LLC acquired a new stake in GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 22,238 shares of the company's stock, valued at approximately $76,000. Hedge funds and other institutional investors own 2.24% of the company's stock.

About GENFIT

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.